Landmark FDA Move: First Quality Control Protocol for Mesenchymal Stromal Cells (MSCs) Sets New Therapeutic Standard

2026-01-26 - 00:31

TIANJIN, China, Jan. 26, 2026 /PRNewswire/ — In a landmark move for the cell therapy industry, a Device Master File (DMF) describing the first dedicated quality control standard for Mesenchymal Stromal Cells (MSCs) was accepted by the U.S. Food and Drug Administration (FDA). The agency’s Master File acknowledgement letter, issued on January 9, 2026, incorporates the